SCHEMBL5965751

SCHEMBL5965751

N#Cc1ccc(OC[C@@H](O)CN)cc1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.59
HPGD P15428 2/20 0.59
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
KDM4E B2RXH2 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
AGER Q15109 1/20 0.50
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MAPT P10636 1/20 0.46
HIF1A Q16665 1/20 0.46
MMP2 P08253 2/20 0.46
MMP3 P08254 1/20 0.46
ABCB11 O95342 1/20 0.45
KCNH2 Q12809 1/20 0.45
ALOX15 P16050 1/20 0.45
MAOB P27338 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5965750 1.00 ALDH1A1 (0.59) ALDH1A1HPGDKMT2AMEN1KDM4E
SCHEMBL772719 1.00 ALDH1A1 (0.59) ALDH1A1HPGDKMT2AMEN1KDM4E
SCHEMBL773191 0.95 ALDH1A1 (0.67) ALDH1A1HPGDKMT2AMEN1KDM4E
SCHEMBL6110358 0.89 ALDH1A1 (0.66) ALDH1A1HPGDKMT2AMEN1KDM4E
SCHEMBL773200 0.88 KMT2A (0.50) ALDH1A1HPGDKMT2AMEN1KDM4E
SCHEMBL11127254 0.87 SMN1; SMN2 (0.61) ALDH1A1KMT2AKDM4ESMN1; SMN2TSHR
SCHEMBL7613436 0.85 ALDH1A1 (0.47) ALDH1A1HPGDKMT2AMEN1KDM4E
SCHEMBL7613440 0.85 ALDH1A1 (0.47) ALDH1A1HPGDKMT2AMEN1KDM4E
SCHEMBL11140925 0.84 ALDH1A1 (0.57) ALDH1A1HPGDKMT2AMEN1KDM4E
SCHEMBL9644259 0.84 ALDH1A1 (0.60) ALDH1A1HPGDKMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7012074-B2 3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2006-03-14 US disclosed
US-20040023971-A1 3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2004-02-05 US disclosed
US-6559162-B2 Electrophysiological activity ASTRAZENECA AB (SE) 2003-05-06 US disclosed
EP-1244631-A1 NEW AZABICYCLOOCTANE DERIVATIVES USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS AstraZeneca AB (SE) 2002-10-02 EP disclosed
US-20020137766-A1 Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2002-09-26 US disclosed
WO-2001047893-A1 NEW AZABICYCLOOCTANE DERIVATIVES USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2001-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023971-A1 3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias KCNH1, KCNH2, RYR2 ALDH1A1 239/4885HPGD 2953/4885KMT2A 3300/4885
US-20020137766-A1 Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias KCNH1, KCNH2, KCNH3 ALDH1A1 315/4885HPGD 932/4885KMT2A 1280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.